These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22968544)

  • 1. Efficacy and safety of beta-interferon in Thai patients with demyelinating diseases.
    Jarernsook B; Siritho S; Prayoonwiwat N
    Mult Scler; 2013 Apr; 19(5):585-92. PubMed ID: 22968544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-beta(1b) treatment in neuromyelitis optica.
    Tanaka M; Tanaka K; Komori M
    Eur Neurol; 2009; 62(3):167-70. PubMed ID: 19590215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis.
    Uzawa A; Mori M; Hayakawa S; Masuda S; Kuwabara S
    Eur J Neurol; 2010 May; 17(5):672-6. PubMed ID: 20039942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Mult Scler; 2012 Oct; 18(10):1480-3. PubMed ID: 22354738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of interferon β-1b in Japanese patients with optic-spinal multiple sclerosis.
    Shimizu Y; Fujihara K; Kubo S; Takahashi T; Misu T; Nakashima I; Yokoyama K; Itoyama Y; Uchiyama S
    Tohoku J Exp Med; 2011 Mar; 223(3):211-4. PubMed ID: 21403431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.
    Papeix C; Vidal JS; de Seze J; Pierrot-Deseilligny C; Tourbah A; Stankoff B; Lebrun C; Moreau T; Vermersch P; Fontaine B; Lyon-Caen O; Gout O
    Mult Scler; 2007 Mar; 13(2):256-9. PubMed ID: 17439893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor responses to interferon-beta treatment in patients with neuromyelitis optica and multiple sclerosis with long spinal cord lesions.
    Wang KC; Lin KH; Lee TC; Lee CL; Chen SY; Chen SJ; Chin LT; Tsai CP
    PLoS One; 2014; 9(6):e98192. PubMed ID: 24887452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
    Viswanathan S; Wong AH; Quek AM; Yuki N
    J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-β1b increases Th2 response in neuromyelitis optica.
    Nakajima H; Hosokawa T; Doi Y; Ikemoto T; Ishida S; Kimura F; Hanafusa T
    Int J Mol Sci; 2012 Sep; 13(10):12213-23. PubMed ID: 23202893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study.
    Drulovic J; Ivanovic J; Mesaros S; Martinovic V; Kisic-Tepavcevic D; Dujmovic I; Pekmezovic T
    Neurol Sci; 2019 Aug; 40(8):1627-1636. PubMed ID: 31011930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
    Limmroth V; Malessa R; Zettl UK; Koehler J; Japp G; Haller P; Elias W; Obhof W; Viehöver A; Meier U; Brosig A; Hasford J; Putzki N; Kalski G; Wernsdörfer C;
    J Neurol; 2007 Jan; 254(1):67-77. PubMed ID: 17273808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
    Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
    Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N
    Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against interferon-beta in neuromyelitis optica patients.
    Asgari N; Kyvik KO; Steenstrup T; Stenager E; Lillevang ST
    J Neurol Sci; 2014 Apr; 339(1-2):52-6. PubMed ID: 24477087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica.
    Lim BC; Hwang H; Kim KJ; Hwang YS; Cheon JE; Kim IO; Kim HJ; Chae JH
    Mult Scler; 2011 Jan; 17(1):67-73. PubMed ID: 20858690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.